clinical trial · NCT07203053
A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2
ETOP IBCSG Partners Foundation·phase2·recruiting·n = 48
Extensive Stage Lung Small Cell CancerTarlatamab
brief summary
START-lung is an international, multicentre, single-arm phase II trial. Protocol treatment consists of tarlatamab administered as an intravenous infusion until disease progression according to RECIST v1.1 criteria, unacceptable toxicity, or patient decision, whichever comes first. The primary objective of the trial is to assess the clinical efficacy of tarlatamab, in terms of 12-month OS rate, in patients with ES-SCLC and ECOG PS 2 who have previously received only one line of platinum-etoposide doublet chemotherapy with immune-checkpoint inhibition and whose disease has progressed.
started
Apr 15, 2026
primary completion
Oct 1, 2029
completion
Oct 1, 2029
last updated
Apr 21, 2026
official title
A Multicentre Phase II Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol